Works Cited

1. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1-S266.

2. U.S. Renal Data System.2022 Annual Data Report. Available athttps://usrds-adr.niddk.nih.gov/2022. Last accessed August 23, 2023.

3. White SL, McGeechan K, Jones M, et al. Socioeconomic disadvantage and kidney disease in the United States, Australia, and Thailand. Am J Public Health. 2008;98(7):1306-1313.

4. Gross ML, Dikow R, Ritz E. Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy. Kidney Int. 2005;(94):S50-S53.

5. Bruce MA, Beech BM, Crook ED, et al. Association of socioeconomic status and CKD among African Americans: the Jackson Heart Study. Am J Kidney Dis. 2010;55(6):1001-1008.

6. Hall YN, Choi AT, Himmelfarb J, Chertow GM, Bindman AB. Homelessness and CKD: a cohort study. Clin J Am Soc Nephrol. 2012;7(7):1094-1102.

7. Jones J, Holmen J, De Graauw J, Jovanovich A, Thornton S, Chonchol M. Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality. Am J Kidney Dis. 2012;60(3):402-408.

8. McClellan AC, Plantinga L, McClellan WM. Epidemiology, geography and chronic kidney disease. Curr Opin Nephrol Hypertens. 2012;21(3):323-328.

9. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010;11(16):2675-2686.

10. Fischer MJ, Go AS, Lora CM, et al. CKD in Hispanics: baseline characteristics from the CRIC and Hispanic-CRIC studies. Am J Kidney Dis. 2011;58(2):214-227.

11. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631-1634.

12. Lora CM, Gordon EJ, Sharp LK, Fischer MJ, Gerber BS, Lash JP. Progression of CKD in Hispanics: potential roles of health literacy, acculturation, and social support. Am J Kidney Dis.2011;58(2):282-290.

13. Portolés J1, Gorriz JL, Rubio E, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.

14. Crews DC, Pfaff T, Powe NR. Socioeconomic factors and racial disparities in kidney disease outcomes. Semin Nephrol. 2013;33(5):468-475.

15. Peralta CA, Ziv E, Katz R, et al. African ancestry, socioeconomic status, and kidney function in elderly African Americans: a genetic admixture analysis. J Am Soc Nephrol. 2006;17:3491-3496.

16. National Kidney Foundation. KDOQI 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). J Int Soc Nephrol. 2017;7(1):1-60.

17. McClellan WM, Newsome BB, McClure LA, et al. Poverty and racial disparities in kidney disease: the REGARDS study. Am J Nephrol. 2010;32:38-46.

18. Shumway JT, Gambert SR. Diabetic nephropathy: pathophysiology and management.Int Urol Nephrol. 2002;34(2):257-264.

19. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1-150.

20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9): 604-612.

21. Becker BN, Vassalotti JA. A software upgrade: CKD testing in 2010. Am J Kidney Dis. 2010;55(1):8-10.

22. Stevens LA, Li S, Kurella Tamura M, et al. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011;57(3 Suppl 2):S9-S16.

23. College of American Pathologists. Current Status of Reporting Estimated Glomerular Filtration Rate. Available at https://documents.cap.org/documents/2010-current-status-reporting-egfr.pdf. Last accessed August 23, 2023.

24. Moyer VA, U.S. Preventative Service Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(8):567-570.

25. Qaseem A, Hopkins RH, Sweet DE, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practical guideline from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;159(12):835-847.

26. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.

27. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin Am J Soc Nephrol. 2012;7(8):1234-1241.

28. Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis. 2013;62(3):457-473.

29. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for giabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-S127.

30. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47(6):1703-1720.

31. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-B29.

32. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850-886.

33. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-1903.

34. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213.

35. Lexicomp Online. Available at https://online.lexi.com. Last accessed August 23, 2023.

36. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.

37. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pract. 2020;26(1):107-139.

38. U.S. Food and Drug Administration. FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function. Available athttps://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain. Last accessed August 23, 2023.

39. U.S. Food and Drug Administration. FDA Approves Treatment for Chronic Kidney Disease. Available athttps://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease. Last accessed August 23, 2023.

40. National Kidney Foundation. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. J Int Soc Nephrol. 2021;99(3):S1-S92.

41. Fraser SD, Roderick PJ, McIntyre NJ, et al. Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Fam Pract. 2013;14:88.

42. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies.Am J Kidney Dis. 2011;58(3):374-382.

43. Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8(9):1583-1590.

44. Slagman MCJ, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomized controlled trial. BMJ. 2011;343:d4366.

45. Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2010;55(3):441-451.

46. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268-1277.

47. Ureña-Torres P, Metzger M, Haymann JP, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis. 2011;58(4):544-553.

48. U.S. Food and Drug Administration. FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna). Available athttps://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warning-and-contraindication-blood-pressure-medicines-containing. Last accessed August 23, 2023.

49. National Kidney Foundation. KDOQI clinical practice guideline for anemia in chronic kidney disease. J Int Soc Nephrol. 2012;2(4):1-64.

50. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2(S2):S279-S335.

51. McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24(12):2096-2103.

52. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.

53. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a meta-regression analysis. Am J Kidney Dis. 2013;61(1):44-56.

54. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148-157.

55. Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial. 2009;22(4):357-362.

56. Suki WN, Moore LW. Phosphorus regulation in chronic kidney disease. Methodist Debakey Cardiovasc J. 2016;12(4 Suppl):6-9.

57. Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol. 2013;14(1):199.

58. Goraya N, Wesson DE. Does correction of metabolic acidosis slow chronic kidney disease progression? Curr Opin Nephrol Hypertens. 2013;22(2):193-197.

59. Tamez H, Zoccali C, Packham D, et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J. 2012;164(6):902-909.

60. Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. J Am Soc Nephrol. 2013;25(1):175-186.

61. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674-684.

62. Hartle JE, Tang X, Kirchner HL, et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am J Kidney Dis. 2012;59(5):636-644.

63. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999;10(11):2426-2439.

64. Ricardo AC, Madero M, Yang W, et al. Adherence to a healthy lifestyle and all-cause mortality in CKD. Clin J Am Soc Nephrol. 2013;8(4):602-609.

65. Filipowicz R, Beddhu S. Optimal nutrition for predialysis chronic kidney disease. Adv Chronic Kidney Dis. 2013;20(2):175-180.

66. McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2015;(2):CD010070.

67. McMahon EJ, Campbell KL, Bauer JD, Mudge DW, Kelly JT. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2021;(6):CD010070.

68. Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(12):2251-2257.

69. Kusano K, Segawa H, Ohnishi R, Fukushima N, Miyamoto K. Role of low protein and low phosphorus diet in the progression of chronic kidney disease in uremic rats. J Nutr Sci Vitaminol. 2008;54(3):237-243.

70. Chan MR, Dall AT, Fletcher KE, Lu N, Trivedi H. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med. 2007;120(12):1063-1070.

71. Wang HH, Hung CC, Hwang DY, et al. Hypokalemia, its contributing factors, and renal outcomes in patients with chronic kidney disease. PLoS One. 2013;8(7):e67140.

72. Rifkin DE, Laws MB, Rao M, Balakrishnan VS, Sarnak MJ, Wilson IB. Medication adherence behavior and priorities among older adults with CKD: a semi-structured interview study. Am J Kidney Dis. 2010;56(3):439-446.

73. Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium due to mild to moderate chronic renal insufficiency. Nephrol Dial Transplant. 2002;17(8):1419-1425.

74. Jain AK, McLeod I, Huo C, et al. When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int. 2009;76(3):318-323.

75. Johansen KL, Painter P. Exercise in individuals with CKD. Am J Kidney Dis. 2012;59(1):126-134.

76. Patwardhan MB, Kawamoto K, Lobach D, Patel UD, Matchar DB. Recommendations for a clinical decision support for the management of individuals with chronic kidney disease. Clin Am J Soc Nephrol. 2009;4(2):273-283.

77. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev. 2011;5(10):CD003236.

78. Chen KC, Peng CC, Hsieh CL, Peng RY. Exercise ameliorates renal cell apoptosis in chronic kidney disease by intervening in the intrinsic and extrinsic apoptotic pathways in a rat model. Evid Based Complement Alternat Med. 2013;2013:368450.

79. Howden EJ, Leano R, Petchey W, Coombes JS, Isbel NM, Marwick TH. Effects of exercise and lifestyle intervention on cardiovascular function in CKD. Clin J Am Soc Nephrol. 2013;8(9):1494-1501.

80. Muntner P, Judd SE, Krousel-Wood M, McClellan WM, Safford MM. Low medication adherence and hypertension control among adults with CKD: data from the REGARDS study. Am J Kidney Dis. 2010;56(3):447-457.

81. Committee on Health Literacy Board on Neuroscience and Behavioral Health. Health Literacy: A Prescription to End Confusion. Washington, DC: The National Academies Press; 2004.

82. Kirsch I, Jungeblut A, Jenkins L, Kolstad A. Adult Literacy in America: A First Look at the Results of the National Adult Literacy Survey (NALS). Washington, DC: National Center for Education Statistics, U.S. Department of Education; 1993.

83. U.S. Census Bureau. Selected Social Characteristics in the United States: 2021. Available at https://data.census.gov/table?tid=ACSDP5Y2021.DP02. Last accessed August 23, 2023.

84. Sevilla Matir J, Willis DR. Using bilingual staff members as interpreters. Fam Pract Manage. 2004;11(7):34-36.

85. Avon J, Winkelmeyer WC, Bohn RL, et al. Delayed nephrologist referral and inadequate vascular access in patients with chronic kidney failure. J Clin Epidemiol. 2002;55(7):711-716.

86. National Kidney Foundation. Clinical practice guidelines for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66(5):884-930.

87. Abdel-Kader K, Fischer GS, Li J, Moore CG, Hess R, Unruh ML. Automated clinical reminders for primary care providers in the care of CKD. Am J Kidney Dis. 2011;58(6):894-902.

88. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification and referral of patients with progressive CKD: a national study. Am J Kidney Dis. 2006;48(2):192-204.

89. Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of chronic kidney disease. J Gen Intern Med. 2011;26(4):386-392.

90. Shahinian VB, Saran R. The role of primary care in the management of the chronic kidney disease population. Adv Chron Kidney Dis. 2010;17(3):246-253.

91. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458-1465.

92. Taal MW. Chronic kidney disease in general populations and primary care: diagnostic and therapeutic considerations. Curr Opin Nephrol Hypertension. 2013;22(6):593-598.

Evidence-Based Practice Recommendations Citations

1. National Kidney Foundation. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int.2020;98(4S):S1-S115. Available at https://kdigo.org/wp-content/uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf. Last accessed September 11, 2023.

2. National Kidney Foundation. KDIGO clinical practice guideline for lipid management in chronic kidney disease.Kidney Int Suppl.2013;3(3):259-305. Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2013-Lipids-Guideline-English.pdf. Last accessed September 11, 2023.

3. Management of Chronic Kidney Disease Working Group.VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease.Washington, DC: Department of Veterans Affairs, Department of Defense; 2019. Available at https://www.healthquality.va.gov/guidelines/CD/ckd/VADoDCKDCPGFinal5082142020.pdf. Last accessed September 11, 2023.


Copyright © 2023 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.